Cara Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Reuters08-15

* Cara Therapeutics Inc reported a quarterly adjusted loss of 37 cents​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of -58 cents. The mean expectation of five analysts for the quarter was for a loss of 27 cents per share. Wall Street expected results to range from -35 cents to -23 cents per share.

* Revenue fell 85.7% to $991.00 thousand from a year ago; analysts expected $1.17 million.

* Cara Therapeutics Inc's reported EPS for the quarter was a loss of 37 cents​.

* The company reported a quarterly loss of $20.02 million.

* Cara Therapeutics Inc shares had risen by 27.4% this quarter and lost 55.8% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had fallen by about 0.7% in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the pharmaceuticals peer group is also "hold"

Wall Street's median 12-month price target for Cara Therapeutics Inc is $1.01 This summary was machine generated from LSEG data August 15 at 04:58 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Jan. 1 0001 -0.27 -0.37 Missed

Mar. 31 2024 -0.40 -0.56 Missed

Dec. 31 2023 -0.41 -0.59 Missed

Sep. 30 2023 -0.52 -0.52 Met

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment